Mucositis is a consequence of high dose chemotherapy that is administered to patients undergoing bone marrow transplant. Currently there are no universal protocols that have been accepted as a standard to prevent and treat oral mucositis in the transplant setting. A novel formulation has been developed in the form of lozenges, whose active ingredient is curcumin. Curcumin has demonstrated anti-inflammatory properties by inhibiting inflammatory cytokines through NF-κB suppression. Promising results from a pilot study have led to the initiation of a phase III randomized trial. The study aims to evaluate the efficacy of curcumin lozenges in reducing the incidence and duration of oral mucositis in autologous bone marrow transplant recipients.